Latest From Norgine BV
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.
- Diagnostic Imaging Equipment & Supplies
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Neurology, Nervous System
- Norgine International Ltd.
- Western Europe
- Parent & Subsidiaries
- Norgine BV
- Senior Management
Peter Stein, Chmn. & CEO
Christopher Bath, CFO
Paul Pay, Chief Bus. Dev. Officer
Alastair Benbow, Chief Dev. & Medical Officer
Kenneth Scrimgeour, Chief Commercial Officer
- Contact Info
Phone: (31) 1895 826 600
Amsterdam, 1101 CA